Piper nigrum Has an Antitumor Effect Through Regulation of the Phosphatidylinositol 3‐Kinase Signaling Pathway in a Murine Model of Acute Myeloid Leukemia
Phytotherapy Research · 2026
DOI: 10.1002/ptr.70423 ↗At a glance
Journal article in Phytotherapy Research, 2026. Written by Natalia Murillo and 3 co-authors. Institution: Grupo de Inmunobiología y Biología Celular, Facultad de Ciencias, Departamento de Microbiología, Pontificia Universidad Javeriana, Bogotá, Colombia. Major MEDLINE topics: Leukemia, Myeloid, Acute, Signal Transduction, Plant Extracts, Piper nigrum. 35 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Pontificia Universidad Javeriana, Ministerio de Ciencia, Tecnología e Innovación, Ministerio de Educación de la Nación.
Abstract (original language)
The search for safer and more effective therapies for acute myeloid leukemia (AML) has intensified due to low response rates and resistance to current chemotherapy. The aim of this study was to evaluate the antitumor and immunomodulatory effects of Piper nigrum extract in a murine model of AML, with particular emphasis on its ability to modulate the phosphatidylinositol 3‐kinase/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR) signaling pathway. The chemical composition of the extract was characterized using advanced analytical techniques. In vitro assays were performed to evaluate cytotoxic and cytostatic effects, glucose consumption and ROS production, modulation of Gal‐9 (galectin 9) and PD‐L1 (programmed death‐ligand 1), focusing on and relating it to the modulation of the (PI3K/AKT/mTOR) pathway. In vivo studies were performed using mice inoculated with DA‐3/ER‐GM cells to evaluate hematological parameters, survival, and immune response after P. nigrum treatment. P. nigrum extract demonstrated cytotoxic and cytostatic activity in vitro, characterized by a decrease in cell proliferation and survival possibly associated with modulation of the PI3K/AKT/mTOR pathway. In the murine AML model, treatment significantly reduced circulating blasts, improved hematological parameters, and prolonged survival. In addition, an increase in effector memory CD8 + T cells was observed, along with a reduction in plasma proinflammatory cytokine levels. Piper nigrum may represent a promising complementary therapeutic strategy for AML, acting as an antitumor and immunometabolic modulator. These findings suggest potential clinical applications of P. nigrum extract as an adjuvant or alternative therapy in the treatment of AML, warranting further preclinical and clinical investigation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Grupo de Inmunobiología y Biología Celular, Facultad de Ciencias, Departamento de Microbiología, Pontificia Universidad Javeriana, Bogotá, Colombia.
ORCID profiles: Natalia Murillo, Paola Lasso, Claudia Urueña, Susana Fiorentino
Funding
- Pontificia Universidad Javeriana
- Ministerio de Ciencia, Tecnología e Innovación
- Ministerio de Educación de la Nación
- Ministerio de Comercio, Industria y Turismo
- Instituto Colombiano de Crédito Educativo y Estudios Técnicos en el Exterior
- World Bank Group
Cite
APA
Murillo, N., Lasso, P., Urueña, C., & Fiorentino, S. (2026). Piper nigrum Has an Antitumor Effect Through Regulation of the Phosphatidylinositol 3‐Kinase Signaling Pathway in a Murine Model of Acute Myeloid Leukemia. Phytotherapy Research. https://doi.org/10.1002/ptr.70423
Vancouver
Murillo N, Lasso P, Urueña C, Fiorentino S. Piper nigrum Has an Antitumor Effect Through Regulation of the Phosphatidylinositol 3‐Kinase Signaling Pathway in a Murine Model of Acute Myeloid Leukemia. Phytotherapy Research. 2026. doi:10.1002/ptr.70423
BibTeX
@article{Murillo2026,
author = {Murillo, Natalia and Lasso, Paola and Urueña, Claudia and Fiorentino, Susana},
title = {Piper nigrum Has an Antitumor Effect Through Regulation of the Phosphatidylinositol 3‐Kinase Signaling Pathway in a Murine Model of Acute Myeloid Leukemia},
journal = {Phytotherapy Research},
year = {2026},
doi = {10.1002/ptr.70423}
}
EUVIMED